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Abstract
Background: Since human immunodeficiency virus (HIV)-infected individuals are at increased risk of severe disease from
pandemic influenza A (H1N1pdm09), vaccination was recommended as a prevention strategy. The aim of the present study
was to evaluate the safety, immunogenicity and persistence of the immune response after vaccination against pandemic
influenza A (H1N1pdm09) with an adjuvanted vaccine in human immunodeficiency virus (HIV)-infected adults using two
single and two double doses.
Methodology/Principal Findings: Open label, randomized trial to evaluate the immune response following H1N1pdm09
vaccination in HIV-infected participants compared to HIV-negative controls (NCT01155037). HIV-infected participants were
randomized to receive 2 single (3.75 mg hemagglutinin) or 2 double (7.5 mg hemagglutinin) doses of the vaccine, 21 days
apart. Controls received one dose of the vaccine. The primary endpoint was seroconversion as measured by
hemagglutination inhibition assay. Two hundred fifty six HIV-infected participants (129 and 127 randomized to single
and double doses, respectively) and 71 HIV-negative controls were enrolled. Among HIV-infected participants,
seroconversion increased from 46.7% and 51.7% after the first dose to 77.2% and 83.8% after the second dose of the
vaccine using single and double doses, respectively. Participants aged .40 years showed higher seroconversion compared
to younger participants. Seroconversion among HIV-infected women and those with nadir CD4,200 cells/mm
3 was
significantly higher with double doses. Persistence of protective antibodies six months after vaccination was achieved by
80% and 89.9% of the HIV-infected participants who received single and double doses, respectively.
Conclusions/Significance: Our results support the recommendation of two double doses of adjuvanted H1N1pdm09
vaccine for HIV-infected individuals, particularly women, and those aged .40 years or with nadir CD4,200 cells/mm
3,t o
achieve antibody levels that are both higher and more sustained.
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Introduction
Humanimmunodeficiencyvirus(HIV)-infectedindividualsareat
increased risk of severe disease from numerous infections, including
recurrent respiratory infections [1]. Although overall mortality
associated with pandemic influenza A/H1N1 virus (H1N1pdm09)
infection was considered low, individuals at risk of complications
were identified, such as immunocompromised individuals that
included HIV-infected [2,3]. As a prevention strategy, vaccination
was recommended to HIV-infected individuals following the same
recommendations forhealthy individuals [4,5].However,there was
uncertaintyregardingthebestvaccinationscheduleforpatientswith
impaired immunity [6,7]. Although few studies have explored
modified vaccination regimens for this population, further studies
are needed to evaluate vaccine dosage and number of applications,
and novel adjuvants [8].
Brazil was seriously affected by H1N1pdm09 with 34,506
influenza-like severe acute respiratory infection cases (5,747 were
laboratory-confirmed cases), most occurring during the winter
season of 2009 [9]. The aim of this study was to measure
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39310seroconversion after 2 single versus 2 double doses of an
adjuvanted H1N1pdm09 vaccine in HIV-infected participants
compared to HIV-negative controls (NCT01155037). In addition,
persistence of antibody levels was evaluated for a follow-up of six
months.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
1. Study Design
This was an open label, randomized, phase-II trial to compare
the safety, immunogenicity, and persistence of the immune
response following H1N1pdm09 vaccination in HIV-infected
patients randomized to receive 2 single (3.75 mg hemagglutinin)
or 2 double (7.5 mg hemagglutinin) doses of the adjuvanted
vaccine, 21 days apart. HIV-infected patients were also compared
to non-randomized controls receiving 1 single dose. The primary
endpoint of the study was seroconversion defined as serum titer
#1:8 before and $1:32 after vaccination or baseline titer .1:8
and at least 4-fold increase after vaccination, as measured by
hemagglutination inhibition assay (HAI, described below) [10].
Seroprotection was defined by serum titer $1:32.
2. Study Participants
HIV-infected patients who received care at the HIV/AIDS
Clinic of the Evandro Chagas Clinical Research Institute,
FIOCRUZ, were approached for study participation. Controls
had a negative HIV rapid test result at the screening visit. Patients
and controls were enrolled simultaneously from March through
August 2010. Estimated sample size was defined as the higher
value obtained from the two different criteria: (1) a non-inferiority
limit of 210% seroconversion comparing the two groups of HIV-
infected patients, and, (2) a 10 percentage point difference in
seroconversion when comparing to HIV-negative controls (assum-
ing 90% seroconversion). The study protocol was approved by the
Research Ethics Committee from Instituto de Pesquisa Clı ´nica
Evandro Chagas and was registered with the Clinical Trials
network (NCT01155037). All participants provided written
informed consent.
Inclusion criteria for all participants were age 18–59 years. The
main exclusion criteria were: receipt of another investigational
vaccine or drug in the past 4 weeks, seasonal influenza vaccination
in the previous 3 months, previous anaphylaxis or serious reactions
to vaccines, or hypersensitivity to egg and chicken protein or
ovalbumin, neurological illness, acute illness on the day of
enrolment, pregnancy and breastfeeding.
3. Vaccine, Group Allocation and Follow-up Observation
Split, inactivated influenza virus, containing 3.75 mg of antigen
equivalent to A/California/7/2009 (H1N1) v-like strain (X-179A)
hemagglutinin with AS03 adjuvant (GSK) was used. Patients
received two single (3.75 mg of antigen each) or two double doses
(7.5 mg of antigen each), according to the randomization scheme.
Study subjects were randomized, by means of computer
generated random numbers (Function ranuni, SAS Version 9.1.4),
which had been previously assigned to one of the vaccination
schemes by the statistician. Randomization used permutation
blocks of size 10 with a 1:1 allocation ratio, stratified by CD4+
count (,200 cells and $200 cells). The protocol was amended
early in field work to discontinue stratification by CD4+ count as
there were very few eligible participants with less than 200 cells
per mm
3. The assignment was printed and placed in opaque
envelopes, sealed and sequentially numbered, and the whole
process was concealed from the study team. After signing the
consent form the next envelope in the sequence was opened and
the vaccination scheme disclosed to the study team and
participants. Each vial of vaccine was used in only one
participant.
Blood samples were collected at baseline, 21 and 42 days, and 6
months after baseline.
Demographic and clinical data were retrieved from medical
records. HIV-1 RNA viral load (Versant HIV-1 RNA 3.0 Assay,
Siemens H. Diagnostics, IL, USA) and CD4 cell counts (BD
Biosciences, CA, USA) were measured at baseline, 21 and 42 days
after baseline.
Surveillance for influenza-like illness (ILI) started from study
enrollment and continued for a follow up of 6 months. Adverse
events were assessed at the clinic 1-hour after vaccination, by
phone contact 20–36 hours after vaccination and in person 7-days
after vaccination.
4. Hemagglutination Inhibition Assay (HAI)
We followed the WHO-recommended protocol to perform HAI
assays [11,12]. In brief, serum samples were treated with receptor-
destroying enzyme (Denka-Seiken, Japan) and incubated with four
hemagglutination units of H1N1pdm09 for 1 hour. After, guinea
pig red blood cells were added to the well at final concentration of
0.5% and incubated for 1 hour, when the HAI was read. Results
were expressed as the reciprocal of the highest dilution that
inhibited hemagglutination. HAI titers ,1:8 were considered to
have a value of 1:4 for calculation purposes [10].
5. Respiratory Sample Collection and Respiratory Virus
Diagnosis
Nasopharyngeal Dacron-swab specimens were collected from
participants displaying acute respiratory infection and placed onto
transport medium (Hanks solution with 100 U/mL penicillin and
100 mg/mL streptomycin) [13]. The RNA from clinical samples
was extracted (QIAmp Viral RNA mini kit, Qiagen, Germany)
and tested for the presence of seasonal and H1N1pdm09 by the
WHO/CDC-recommended rRT-PCR [14]. Real time RT-PCR
was performed to detect the following agents: subtypes of
Influenza A, Influenza B, coronavirus (229, 43 e 63), parainfluenza
(1, 2, 3 and 4), metapneumovirus, parechovirus, rhinovirus, RSV
A/B, bocavirus, adenovirus and enterovirus (Fast-Track diagnosis,
Luxembourg, Luxembourg).
6. Statistical Analysis
Statistical analyses were performed with SAS 9.1.3 (Cary, NC,
USA: SAS Institute Inc., 2004) and SPSS Statistics 19 (Release
Version 19.0.0; SPSS, Inc., 2010). Differences (and 95%
confidence limits) between the proportions and the logarithm of
antibody titers for double doses and single doses were calculated
[15]. The non-inferiority limit for seroconversion and ratios of
geometric mean titers were 210% and 0.5, respectively. Statistical
significance of differences between proportions was assessed using
the chi-squared test. Comparison of means was based on the t-test.
Cumulative curves of antibody titers were compared across groups
using the Log-rank test. All tests used 95% confidence limits.
Logistic regression was used to adjust the degree of association of
the vaccination schemes to seroconversion at 42 days after baseline
for demographic and clinical factors. Likewise, the association of
antibody titers to relevant covariates was explored in multiple
regression models.
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Two-hundred and fifty six patients were randomized, 129
received two single doses and 127 received two double doses
(Figure 1). All 256 patients received the first dose of the vaccine,
and 95.3% (244) received the second dose. Withdrawals were due
to clinical conditions detected after recruitment (1 patient) and
missed appointments (11 patients). Among the 71 controls, there
were 3 missed appointments for health-unrelated reasons.
Patients showed a balanced distribution of baseline demo-
graphic and clinical variables (Table 1) including pre-vaccination
antibody levels (Table 2 and Figure 2, ‘‘Day 0’’ plot). Patients
were predominantly middle-aged adult men, whereas among
controls younger females prevailed. At enrollment, almost 80%
of the patients were on HAART, CD4 cell counts surpassed 300
cells/mm
3 for more than 75% of them and approximately 65%
had undetectable HIV RNA viral load (Table 1). Approximately
half of the patients had a nadir CD4 cell count below 200 cells/
mm
3.
At baseline, more than 1/3 of the patients and 1/5 of the
controls had seroprotective antibody levels (i.e. $1:32, Table 2).
Antibody levels and the proportion seroprotected were slightly
higher in the subgroup aged .40 years. Twenty one days after the
first dose, the proportion seroprotected, antibody levels and
geometric mean titer (GMT) rose substantially in all groups
(Table 2 and Figure 2, Day 21). Among patients, the rise implied
approximately 50% seroconversion (slightly higher among recip-
ients of double doses) (Table 2). Seroconversion and antibody
levels were much higher among controls, despite the modest
seroprotection (Table 2 and Figure 2, Day 21). In all groups
seroconversion rates and GMT following the first dose were
somewhat higher among participants aged .40 years.
After the second dose, patients experienced a substantial rise of
seroprotection and seroconversion, which exceeded that of
controls. Antibody levels among those receiving double doses far
exceeded that of controls (Table 2 and Figure 2, Day 42).
Participants aged .40 years showed higher seroconversion rates
and higher GMT, compared to younger participants, particularly
among controls and patients who received double doses.
Six months (140–196 days) after recruitment, seroprotection
rates among patients decreased slightly and GMT fell to half the
level on day 42. Among controls, seroprotection rates increased
substantially but the GMT decreased about 30% compared to day
42 levels (Table 2).
Seroconversion rates and GMT were consistently lower in the
single dose group, at all times, and the confidence limits of the
difference in proportions of seroconversion and GMT ratios did
not provided evidence to reject the hypothesis of inferiority of the
single dose (Table 3). In fact, superiority of two double doses is
suggested by a GMT exceeding the upper 95% confidence limit of
the GMT after two single doses (Table 2) and the statistical
significance (Log-rank, p=0.003) of cumulative curves for double
and single doses (Figure 2, Day 42).
Figure 1. Participant disposition: enrollment, study procedures and participant disposition.
doi:10.1371/journal.pone.0039310.g001
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second dose occurred 1.82 times more often among two double
doses recipients but the association lacked statistical significance
(Table 4). Older age (.40 years) also increased the odds of
seroconversion, being the only statistically significant predictor
after adjustment of covariates. Consistently, the differences in
antibody titers between HIV-infected groups and HIV-negative
controls 42 days after vaccination adjusted for antibody titer
before vaccination and for age were not statistically significant
(data not shown).
Among patients, seroconversion provided by two double doses
was higher for those aged .40, women, those with nadir CD4 cell
count ,200 cells/mm
3, with undetectable viral load, and on
HAART (Table 5). Seroconversion among women and those with
nadir CD4 cell count ,200 cells/mm
3 was significantly higher
when two double doses were used.
The average reduction in CD4 cell counts 21 days after the first
dose was more pronounced among participants who received two
double doses, but the difference was not statistically significant nor
clinically relevant (Table 6). After the second dose, a small average
increase in CD4 cell counts was observed for the single dose group
while the double dose group showed a negligible difference. In
groups, small and similar percentages of patients showed increased
and decreased HIV viral load.
The most frequent local adverse reaction was pain, reported
after the first dose, in 72% and 91% of the patients who received
single and double doses, respectively (Figure 3). In these same
groups, after the second dose, 52% and 66% of the participants
reported pain. Eighty-six percent of the controls also reported
pain. The most frequent systemic adverse event was fever, which
was reported, after the first dose, by 7% and 12% of the patients
who received single and double doses, respectively.
A total of 43 participants presented with ILI within 6 months of
the first vaccine dose: 14 and 17 ILI events in patients receiving
single and double doses, respectively, and 10 ILI events among
controls. Nasopharyngeal samples were collected for 22 partici-
pants (Table 7). No H1N1pdm09-related ILI was identified. In six
patients seasonal influenza A H3N2 (2 patients) or influenza B (4
patients) viruses were detected, which is in line with the influenza
season that occurred during the period of study. Of note, one
patient that received double doses was co-infected with both
rhinovirus and influenza B.
Discussion
To our knowledge, this is the first randomized, controlled trial
designed to evaluate efficacy and sustainability of protective titers
of an adjuvanted H1N1pdm09 vaccine in HIV-infected adults in
Latin America. From April through December 2009, during the
fall/winter of the southern hemisphere, the H1N1pdm09 virus
circulated in Brazil [16], and, by the end of 2009, over 2000
H1N1pdm09-related deaths were reported [9]. International and
local guidelines recommended prioritization of vaccination against
H1N1pdm09 for HIV-infected individuals [4,5]. Vaccination was
carried out with a single dose, following the schedule for HIV-
negative individuals. However, seroconversion to influenza vac-
cines among HIV-infected individuals have been shown to be
lower than those observed in the general population [17,18]. In
light of this scenario, we evaluated an alternative vaccination
scheme for HIV-infected individuals.
In our HIV-infected population, seroconversion increased from
47% and 52% after the first dose to 77% and 84% after the second
dose of the vaccine using single and double doses, respectively.
Similarly, seroprotection increased from 71% and 76% after the
first dose to 84% and 88% after the second dose of the same
vaccination schemes. These percentages of seroconversion are
comparable to those found by Soonawala et al [19] in a smaller
and non-randomized study and lower than the seroconversions
found by Bickel [6] and Launay [7] who enrolled asymptomatic,
HIV-infected adults in Germany and France. In these studies,
most patients’ characteristics were comparable to those from our
study population (ie, high mean baseline CD4 cell count). In
contrast, although HAART was used by almost 80% of our
patients, undetectable viral load was observed in roughly 65% and
40% had a previous AIDS-defining illness. That is, in comparison
Table 1. Baseline demographic and clinical characteristics of
the study population.
Characteristic
HIV-positive
Single dose
HIV-positive
Double dose
HIV-
negative
Number of participants 129 127 71
Age
Median (IQR) 41.7 (36.0, 47.6) 42.8 (34.9, 50.1)33.7 (29.1,
47.0)
Mean (SD) 42.2 (8.5) 42.0 (9.2) 37.3 (10.5)
#40 years, N (%) 60 (46.5) 52 (40.9) 46 (64.8)
.40 years, N (%) 69 (53.5) 75 (59.1) 25 (35.2)
Gender
Male, N (%) 90 (69.8) 79 (62.2) 25 (35.2)
Current smoker
Yes, N (%) 37 (28.7) 27 (21.3) 9 (12.7)
BMI
$25 Kg/m
2, N (%) 58 (45.0) 62 (48.8) 42 (59.2)
Years since HIV diagnosis NA
Median (IQR) 6.9 (3.1, 12.4) 5.9 (2.4, 12.9)
Mean (SD) 8.0 (5.7) 8.0 (6.6)
Previous AIDS-defining illness NA
Yes, N (%) 56 (43.4) 51 (40.1)
CD4 count (cells/mm
3)N A
Median (IQR) 567 (329, 758) 550 (356, 743)
Mean (SD) 583.5 (327.3) 584.5 (310.8)
Nadir CD4 count (cells/mm
3)N A
Median (IQR) 165 (70, 291) 205 (48, 325)
Mean (SD) 222.3 (221.2) 226.8 (202.6)
HIV RNA viral load NA
,50 copies/ml, N (%) 84 (68.3) 78 (63.4)
Missing, N (%) 6 (4.7) 4 (3.1)
HAART NA
Currently taking, N (%) 103 (79.8) 101 (79.5)
Never received HAART, N (%) 20 (15.5) 21 (16.5)
Not on HAART, N (%) 6 (4.7) 4 (3.1)
Missing, N (%) 0 (0.0) 1 (0.8)
Years on HAART NA
Median (IQR) 4.6 (2.2, 9.9) 3.9 (1.8, 10.3)
Mean (SD) 6.1 (4.8) 6.4 (5.5)
IQR: interquartile range, BMI: body-mass index, HIV: human immunodeficiency
virus, HAART: highly active antiretroviral therapy, NA: not applicable.
doi:10.1371/journal.pone.0039310.t001
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advanced disease.
In addition, a different pattern of H1N1pdm09 virus circulation
in the northern and southern hemispheres in 2009/2010 may
hamper the comparison of our seroconversion results with those of
others [6,7,19]. Studies from the northern hemisphere enrolled
patients from November to December of 2009, which overlapped
with the second wave of the H1N1pdm09 pandemic in these
locations [20]. Since circulating and vaccine strains of
H1N1pdm09 virus were virtually the same, sub-clinical infection
with the circulating viruses may have boosted the immune
response in individuals from the northern hemisphere, leading to
Table 2. Antibody responses to the different vaccine schedules among HIV-infected and HIV-uninfected participants according to
time since vaccination.
HIV-infected HIV-uninfected
Single dose Double dose Single dose
N Estimates N Estimates N Estimates
Baseline
Seroprotection*, N (%) 127 44 (34.6) 126 42 (33.3) 70 16 (22.9)
Age ,=40 years 58 18 (31.0) 51 13 (25.5) 45 11 (24.4)
Age .40 years 69 26 (37.7) 75 29 (38.7) 25 5 (20.0)
GMT (95% CI) 127 16.8 (13.9, 20.4) 126 17 (14.0, 20.6) 70 13.4 (10.3, 17.4)
Age ,=40 years 58 15.4 (11.8, 20.2) 51 12.9 (9.5, 17.4) 45 13.5 (9.5, 19.1)
Age .40 years 69 18.0 (13.7, 23.8) 75 20.5 (16.2, 26.1) 25 13.2 (9.0, 19.3)
Day 21 (21 days after 1st dose)
Seroprotection (N. %) 121 86 (71.1) 121 92 (76.0) 68 56 (82.4)
Age ,=40 years 55 34 (61.8) 48 30 (62.5) 43 34 (79.1)
Age .40 years 66 52 (78.8) 73 62 (84.9) 25 22 (88.0)
Seroconversion** (N. %) 120 56 (46.7) 120 62 (51.7) 67 50 (74.6)
Age ,=40 years 54 23 (42.6) 47 22 (46.8) 42 29 (69.0)
Age .40 years 66 33 (50.0) 73 40 (54.8) 25 21 (84.0)
GMT (95% CI) 121 48.9 (36.8, 65.0) 121 56.1 (42.4, 74.3) 68 107.6 (73.2, 158.3)
Age ,=40 years 55 38.2 (24.6, 59.3) 48 33.9 (21.4, 53.8) 43 103.8 (61.9, 174.0)
Age .40 years 66 60.1 (41.6, 86.9) 73 78.1 (55.9, 109.2) 25 114.6 (64.8, 202.4)
Day 42 (21 days after 2nd dose)
Seroprotection (N. %) 115 96 (83.5) 112 98 (87.5) 65 53 (81.5)
Age ,=40 years 51 41 (80.4) 41 32 (78.0) 40 31 (77.5)
Age .40 years 64 55 (85.9) 71 66 (93.0) 25 22 (88.0)
Seroconversion (N. %) 114 88 (77.2) 111 93 (83.8) 64 46 (71.9)
Age ,=40 years 50 38 (76.0) 40 30 (75.0) 39 25 (64.1)
Age .40 years 64 50 (78.1) 71 63 (88.7) 25 21 (84.0)
GMT (95% CI) 115 128.8 (94.0, 176.5) 112 206.1 (150.5, 282.5) 65 129.4 (84.1, 199.1)
Age ,=40 years 51 104.4 (64.1, 170.0) 41 121.7 (66.0, 224.4) 40 105.8 (60.2, 185.8)
Age .40 years 64 152.2 (101.0, 229.5) 71 279.5 (200.4, 389.8) 25 178.5 (92.1, 345.9)
6 months after 1
st dose
Seroprotection (N. %) 112 87 (77.7) 113 96 (85.0) 61 58 (95.1)
Age ,=40 years 48 38 (79.2) 42 32 (76.2) 37 34 (91.9)
Age .40 years 64 49 (76.6) 71 64 (90.1) 24 24 (100.0)
GMT (95% CI) 112 64.8 (47.6, 88.1) 113 86.9 (65.2, 115.9) 61 91.0 (68.7, 120.6)
Age ,=40 years 48 66.8 (41.2, 108.3) 42 66.1 (38.4, 113.9) 37 94.8 (62.7, 143.3)
Age .40 years 64 63.3 (42.4, 94.5) 71 102.2 (74.1, 141.1) 24 85.4 (61.0, 119.6)
Persistence of seroconversion*** (N. %) 85 68 (80.0) 89 80 (89.9) 45 45 (100)
Age ,=40 years 36 30 (83.3) 28 24 (85.7) 25 25 (100)
Age .40 years 49 38 (77.6) 61 56 (91.8) 20 20 (100)
HIV: human immunodeficiency virus, GMT: geometric mean titer.
*Hemagglutination inhibition assay (HAI) titre .1:32.
**HAI titer #1:8 before and at least 1:32 after vaccination or baseline HAI titer .1:8 and at least 4 fold increase after vaccination.
***Persistence of seroprotective titers among patients who seroconverted on day 42.
doi:10.1371/journal.pone.0039310.t002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39310Figure 2. Reverse cumulative distribution curves of HAI antibody titers in samples collected on days 0, 21, 42, and at 6 months by
vaccine group of participants: HIV-infected who received single doses (dashed line), HIV-infected who received double doses (solid
line), and HIV-negative (dotted line). Values are given on a log scale.
doi:10.1371/journal.pone.0039310.g002
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prior to the southern hemisphere’s winter of 2010. H1N1pdm09
circulation in 2010 in Brazil decreased significantly when
compared to 2009 [20]. In fact, the Brazilian surveillance system
detected influenza A H3N2 and B circulation in 2010, but no
concomitant H1N1pdm09 circulation [20]. Thus, there was
minimal H1N1pdm09 circulation during our study and, conse-
quently, immune boosts due to virus circulation were unlikely. In
our study, one third of the HIV-infected participants had
seroprotective antibody titers at baseline. This value is higher
than that observed in other H1N1pdm09 studies conducted in the
northern hemisphere [6,7], corroborating the high H1N1pdm09
circulation in 2009 in Brazil [9].
Table 3. Differences in proportions of seroconversion and seroprotection and ratio of GMT for single dose when compared to
double dose according to time since vaccination.
Differences/ratios and confidence intervals
Day 21 (21 days after first dose)
Seroprotection* (Psingle –P double) and 95% CI
Overall 25.0 (216.9, 7.0)
Age ,=40 years 20.7 (221.4, 20.0)
Age .40 years 26.1 (220.4, 8.1)
Seroconversion** (Psingle –P double) and 95% CI
Overall 25.0 (218.5, 8.5)
Age ,=40 years 24.2 (225.6, 17.2)
Age .40 years 24.8 (222.8, 13.3)
GMT GMTsingle/GMTdouble and 95% CI
Overall 0.87 (0.58, 1.30)
Age ,=40 years 1.13 (0.59, 2.15)
Age .40 years 0.77 (0.47, 1.27)
Day 42 (21 days after second dose)
Seroprotection (Psingle –P double) and 95% CI
Overall 24.0 (214.0, 6.0)
Age ,=40 years 2.3 (216.6, 21.3)
Age .40 years 27.0 (218.9, 4.9)
Seroconversion (Psingle –P double) and 95% CI
Overall 26.6 (217.8, 4.6)
Age ,=40 years 1.0 (219.1, 21.1)
Age .40 years 210.6 (224.6, 3.4)
GMT GMTsingle/GMTdouble and 95% CI
Overall 0.62 (0.40, 0.98)
Age ,=40 years 0.86 (0.39, 1.88)
Age .40 years 0.54 (0.32, 0.92)
Six months after 1
st dose
Seroprotection (Psingle –P double) and 95% CI
Overall 27.3 (218.3, 3.8)
Age ,=40 years 3.0 (216.5, 22.5)
Age .40 years 213.6 (227.5, 0.4)
GMT GMTsingle/GMTdouble and 95% CI
Overall 0.75 (0.49, 1.14)
Age ,=40 years 1.01 (0.48, 2.11)
Age .40 years 0.62 (0.37, 1.04)
Persistence of seroconversion*** (Psingle –P double) and 95% CI
Overall 29.9 (221.6, 1.8)
Age ,=40 years 22.4 (223.3, 18.6)
Age .40 years 214.3 (229.7, 1.1)
*HAI titre .1:32.
**HAI titer #1:8 before and at least 1:32 after vaccination or baseline HAI titer .1:8 and at least 4 fold increase after vaccination.
***Persistence of seroprotective titers among patients who seroconverted on day 42.
doi:10.1371/journal.pone.0039310.t003
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seroconverters) six months after vaccination was lower in patients
when compared to controls. These results are consistent with other
reports of decreased sustained antibody response among HIV-
infected adults [21]. Data on the durability of influenza antibodies
after seasonal vaccination for the general population suggest that
protection lasts for at least one year [22,23]. For the HIV-infected
population, very limited data is available as most studies only
report 30-days of follow-up. Sustainability of antibody response is
important since the influenza season often spans an estimated six
months [24]. Furthermore, pandemic influenza infections may
occur during non-seasonal months necessitating prolonged immu-
nity [25]. Our study shows that a higher proportion of the patients
who received two double doses were able to sustain protective
antibody responses at six months. Thus, our data suggest that a
modified vaccination schedule may confer higher sustained
seroprotection. This finding has important implications for both
HIV care and public health policy.
Our results suggest that two double doses of an adjuvanted
H1N1pdm09 vaccine elicited a significantly higher seroconversion
among women when compared to two single doses. Historically,
women were underrepresented in HIV clinical trials of antiretro-
viral therapy, as well as in other therapeutic trials in the areas of
cardiovascular, lung, and cancer research [26,27,28]. Currently,
there is increased awareness of the need for representative
inclusion of women in HIV clinical trials. More than one third
of our participants were women, a higher percentage when
compared to all trials previously published on H1N1pdm09
vaccination among HIV-infected individuals. It is likely that our
study is the first to evaluate a potential sex-based difference in
seroconversion as a function of vaccination schemes, being thus a
unique finding of our study.
The increased seroconversion among participants aged .40
years might be due to previous exposure to a low glycosylated
H1N1 virus during their lifetime. A series of publications have
described the similarities between the hemagglutinin from the
1918 and 2009 viruses, which are both low glycosylated
[29,30,31]. Although more glycosylated than those from 1918
and 2009, viruses from the 1970s are also more similar to these
agents than to viruses that circulated in 1990/2000 that are
heavily glycosylated. Therefore, previous exposure to viruses from
the 1970s could confer cross-immunity to H1N1pdm09. Conse-
quently, it is possible that vaccination against H1N1pdm09 could
have boosted an existing immunity to low glycosylated hemag-
glutinins, which is more likely to be present in participants aged
.40 years.
During the six months of follow-up, there were 43 ILI out of
which 22 were laboratory diagnosed. Fifteen participants had at
least one respiratory virus detected, but no H1N1pdm09 cases
were found. The vaccine was well tolerated in our study
population. Local pain and fever, which were the most frequent
Table 4. Demographic and clinical factors associated with the unadjusted and adjusted odds of seroconversion (odds ratio, OR,
and 95% confidence interval, 95% CI).
N Unadjusted OR (95%CI) Adjusted OR (95%CI)
Seroconversion
Age ,40 years (vs. $40 years) 290 0.49 (0.28, 0.86) 0.54 (0.30, 0.98)
Male (vs. Female) 290 0.96 (0.55, 1.71) 0.90 (0.49, 1.64)
BMI (per unit increase in BMI) 290 1.03 (0.97, 1.10) 1.05 (0.98, 1.12)
Current smoker (vs. not) 290 1.74 (0.83, 3.64) 1.80 (0.83, 3.92)
HIV+, Single dose (vs. HIV2) 290 1.28 (0.64, 2.56) 1.15 (0.55, 2.41)
HIV+, Double dose (vs. HIV2) 290 2.02 (0.96, 4.25) 1.82 (0.83, 3.98)
BMI: body-mass index, HIV: human immunodeficiency virus.
doi:10.1371/journal.pone.0039310.t004
Table 5. Proportion of HIV-infected individuals who
seroconverted (as measured on day 42 after the first vaccine
dose) as a function of demographic and clinical factors and
vaccine schedule.
Single
dose % (N)
Double
dose % (N)
p-
value*
Seroconversion
Age
#40 years 74.5 (38/51) 75 (30/40) 1.000
.40 years 78.1 (50/64) 88.7 (63/71) 0.108
Sex
Male 80.0 (64/80) 81.2 (56/69) 1.000
Female 68.6 (24/35) 88.1 (37/42) 0.049
Current smoker
No 74.4 (61/82) 81.6 (71/87) 0.271
Yes 81.8 (27/33) 91.7 (22/24) 0.255
BMI
,25 75.8 (47/62) 85.5 (47/55) 0.246
$25 77.4 (41/53) 82.1 (46/56) 0.351
Baseline CD4 cell count (cells/mm
3)
,350 78.1 (25/32) 87.5 (21/24) 0.489
$350 75.9 (63/83) 82.8 (72/87) 0.343
Nadir CD4 cell count (cells/mm
3)
,200 70.8 (46/65) 88.7 (47/53) 0.023
$200 84.0 (42/50) 79.3 (46/58) 0.623
Baseline viral load (copies/ml)
,50 77.9 (60/77) 88.4 (61/69) 0.124
$50 73.5 (25/34) 76.3 (29/38) 0.793
Currently taking HAART
No 72.7 (16/22) 66.7 (14/21) 0.747
Yes 77.4 (72/93) 87.8 (79/90) 0.080
*p-values based on Fisher’s exact test.
doi:10.1371/journal.pone.0039310.t005
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among patients randomized to the double dose arm. In regard to
the impact of vaccination on HIV viral load and CD4 cell counts,
our results corroborate recent findings of no clinically meaningful
effect of vaccination on CD4 cell counts and HIV viral load
[6,21,32]. We also did not find an association of seroconversion
with baseline CD4 cell counts. Our results show that double doses
elicited significant higher seroconversion among patients with
nadir CD4 cell counts ,200 cells/mm
3.
Table 6. Effect of vaccination on plasma HIV RNA level and CD4 cell count as given by the change in these parameters, from
baseline, with respect to different times after vaccination.
HIV-infected HIV-infected
Single dose Double dose p-value
21 days after first dose
D CD4
a cells/mm
3, mean (SE) 24.3 (15.2) 233.8 (18.8) 0.226
D Log viral load
b copies/ml, mean (SE) 0.14 (0.04) 0.17 (0.04) 0.598
Viral load unchanged, N (%) 105 (89.7) 104 (87.4) 0.852
Viral load increased
c, N (%) 8 (6.8) 10 (8.4)
Viral load decreased, N (%) 4 (3.4) 5 (4.2)
42 days after first dose
D CD4
a cells/mm
3, mean (SE) 17.8 (22.1) 1.1 (21.6) 0.590
D Log viral load
b copies/ml, mean (SE) 0.32 (0.06) 0.34 (0.06) 0.893
Viral load unchanged, N (%) 88 (79.3) 82 (76.6) 0.615
Viral load increased
c, N (%) 10 (9.0) 14 (13.1)
Viral load decreased, N (%) 13 (11.7) 11 (10.3)
Log: log base 10, SE: standard error.
aDifference between CD4 cell counts at each time and baseline CD4 cell count.
bDifference between Log viral load at each time and baseline Log viral load.
cIncrease is defined as a change from undetectable to detectable or, if detectable, a 0.5 log increase.
doi:10.1371/journal.pone.0039310.t006
Figure 3. Adverse events: local and systemic adverse events 21 days after first dose and 42 days after the first dose in the three
groups: HIV-infected who received single doses, HIV-infected who received double doses, and HIV-negative.
doi:10.1371/journal.pone.0039310.g003
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single-center study, with entry criteria limited to those patients
without current comorbidities, and conducted over a single
H1N1pdm09 season. We evaluated a well controlled cohort of
HIV-infected individuals and, thus, could not determine the
impact of current severe immunosuppression on H1N1pdm09
vaccine responses. However, our study had the advantage of
concurrently evaluating a group of HIV-uninfected controls and a
significant proportion of women. Our study provides compelling
evidence for the need of a different vaccination scheme for HIV-
infected individuals. A higher vaccine dose would provide
additional benefits for women and for those with a history of
advanced immunodeficiency.
In summary, our results show that patients only achieved levels
of seroconversion comparable to those of controls after two doses
of an adjuvanted vaccine. The 21-days interval between doses was
more important in inducing higher seroconversion than the
vaccine hemagglutinin dosage. Patients with nadir CD4 cell counts
,200 and women showed improved seroconversion with double
doses, which also provided more sustained seroprotection. Our
findings contribute to the planning of next year’s influenza
vaccination campaign also by suggesting that if the vaccine is used
at the currently recommended dosage and schedule, a significant
proportion of the individuals will remain vulnerable to influenza.
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